Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma

Kwang Hyun Kim, Hyung Ho Lee, Young Eun Yoon, Joon Chae Na, Sook Young Kim, Young In Cho, Sung Joon Hong, Woong Kyu Han

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (> 50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years.

Original languageEnglish
Pages (from-to)662-667
Number of pages6
JournalOncotarget
Volume9
Issue number1
DOIs
Publication statusPublished - 2018

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this